Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.

[1]  P. Parrilla,et al.  Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. , 2007, Transplantation proceedings.

[2]  J. Campistol,et al.  Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. , 2007, Transplantation proceedings.

[3]  K. Budde,et al.  Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes , 2007, Transplantation.

[4]  W. Arns,et al.  Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium. , 2006, International journal of clinical pharmacology and therapeutics.

[5]  M. Schnitzler,et al.  Mycophenolate Mofetil Dose Reductions and Discontinuations after Gastrointestinal Complications Are Associated with Renal Transplant Graft Failure , 2006, Transplantation.

[6]  C. Marroni,et al.  Enteric-coated mycophenolate sodium experience in liver transplant patients. , 2006, Transplantation Proceedings.

[7]  M. Schnitzler,et al.  Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  H. Sollinger.  Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. , 2004, Transplantation proceedings.